Biocompatible hyperbranched polyglycerol modified β-cyclodextrin derivatives for docetaxel delivery

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapy

Background:

• Hydrophobic drug delivery for cancer therapy faces challenges with biocompatible vectors.
• Beta-cyclodextrin (β-CD) has limitations in drug delivery applications.

Purpose of the Study:

• To design and synthesize a novel biocompatible drug delivery system based on hydroxypropyl guar (HPG) modified β-CD (β-CD-HPG).
• To evaluate the biocompatibility, drug encapsulation, and controlled release properties of β-CD-HPG for cancer chemotherapy.

Main Methods:

• Synthesis of β-CD-HPG by conjugating HPG branches onto a β-CD core.
• Structural confirmation using NMR, FTIR, GPC, and solubility tests.
• In vitro biocompatibility assays (red blood cell morphology, hemolysis) and anti-cancer drug (docetaxel) encapsulation studies (DSC).
• Nanoparticle formation, drug loading capacity, release kinetics, and in vitro antitumor assays.

Main Results:

• HPG modification significantly improved β-CD's biocompatibility, reducing red blood cell damage.
• β-CD-HPG demonstrated excellent cell safety across a concentration range of 0.01-1 mg/mL.
• Docetaxel was effectively encapsulated, forming nanoparticles (<200 nm) with enhanced loading capacity and controlled release kinetics compared to β-CD.
• The β-CD-HPG/docetaxel formulation effectively inhibited the proliferation of human breast adenocarcinoma cells in vitro.

Conclusions:

• The developed β-CD-HPG copolymer is a promising biocompatible vector for hydrophobic anti-cancer drugs.
• This system offers improved drug delivery characteristics, including enhanced loading and controlled release.
• β-CD-HPG/docetaxel holds significant potential for advancing cancer chemotherapy treatments.